According to the company, significant positive results were achieved, clearly demonstrating the efficacy and safety of this simple, low-cost method to reduce pain within the first few days after breast augmentation.
The study tracked 48 women undergoing breast augmentation, with active ActiPatch therapy used on one augmented breast and not activated ActiPatch therapy used on the other augmented breast. In total, 73% of women reported less pain and uncomfortability on the breast that received ActiPatch therapy than on the control side. Of the 27% of patients with no decrease in pain on the active side, 21% reported that the pain was similar between sides, with only 6% reporting that the pain was more severe on active side.
Andrew Wheelan, CEO of BioElectronics, said: “The release of the study is a highly significant event for our company and we believe it will be very beneficial in receiving additional FDA indications for post-surgical use of our product. Our over-the-counter sales outside of the US are growing and we believe this study holds the potential to significantly advance our domestic revenue generation.
“Over the next few months we plan on releasing additional clinical studies relating to ankle sprains, heel pain, post surgical care for C-sections and additional breast augmentation data. It is clearly an exciting time at BioElectronics, and we are very positive about both our short-term and long-term future.”